Taiwan bourse last quoted at 41,917 this morning (11th), up 313 points or about 0.75%. Global chip foundry leader TSMC (2330.TT) bucked the trend, sagging 1.5% to TWD2,255.

Apple Inc. (AAPL.US) and Intel Corporation (INTC.US) reached a preliminary agreement under which Intel will manufacture certain chips used to power Apple devices, the Wall Street Journal cited informed sources over the weekend as saying.

The two companies reportedly engaged in intensive negotiations for more than a year and finalized a formal agreement in recent months.

Major Asia-Pacific chip stocks thrived broadly this morning. SMIC (00981.HK) and HUA HONG SEMI (01347.HK) each spiked about 5%. In South Korea, Samsung Electronics (005930.KS) and SK Hynix (000660.KS) surged 5.7% and 11.2%, respectively, both notching record highs. In Japan, Kioxia (285A.JP) rallied 7.6% to a new high. MediaTek (2454.TW) in Taiwan also jumped up 8.8% to a record high.
~

AASTOCKS Financial News
Website: www.aastocks.com

The robotics sector picked up sharply, China Merchants Securities International (CMSI) wrote in a report. After the May Day holiday, robotics-related stocks in Hong Kong and A-shares markets have turned more vibrant, with share prices charting notable gains.

The broker attributed this to three factors. First, Tesla, Inc. (TSLA.US) was expected to start mass production of its robots in July or August, while supply chain order information is typically released one to two months in advance, giving rise to an early recovery in sector sentiment. Second, after a marked correction since February that formed a bottom range, the robotics sector has once again attracted capital primarily focused on AI industry chain investments. Third, some robotics supply chain companies have traditional core businesses in the automotive industry. Following the release of 1Q results, potential negative factors have been largely digested, shifting market focus back to individual companies growth prospects.

CMSI highlighted key companies to watch. 1) For complete machine manufacturers it recommended focusing on humanoid robot leader UBTECH ROBOTICS (09880.HK), its top pick in the robotics industry chain, as humanoid robot commercial applications are landing the fastest and the company raised its delivery guidance after its annual results. It also named DOBOT (02432.HK), which is a leader in collaborative robots, driven by both industrial and commercial segments, and is expanding rapidly into humanoid robotics. In vertical robotics, GEEKPLUS-W (02590.HK), a leader in warehouse robotics, is also worth attention. 2) For supply chain, its top pick is MINTH GROUP (00425.HK), whose progress in robotics, AI liquid cooling and the low-altitude economy beat expectations. Investors should watch for potential major breakthroughs in the AIDC field. The company's fuel cell system components, including SOFC and PEMFC, achieved order breakthroughs in domestic and overseas markets. SANHUA (02050.HK), a core supplier in the Tesla industry chain, is also highlighted. 3) For broader robotics plays, the broker expected that market interest will spread to the broader robotics segment in the later stage of the rally, with growing attention on HORIZONROBOT-W (09660.HK), HESAI-W (02525.HK) and ROBOSENSE (02498.HK).
~

AASTOCKS Financial News
Website: www.aastocks.com

YOFC's 2025 ESG and Sustainability Report shows the optical fiber giant reducing emissions as technological innovation and smarter manufacturing drive measurable gains.

WUHAN, China, May 11, 2026 /PRNewswire/ -- Yangtze Optical Fibre and Cable Joint Stock Limited Company (YOFC) reduced greenhouse gas emissions intensity by 13.12% year on year and cut total carbon emissions by 86,333 tonnes in 2025. YOFC monitors carbon performance via its self-developed SmartCarbon platform. The platform obtained third-party verification from Bureau Veritas in 2025 and enables granular carbon data tracking at both organizational and product levels.

The results, disclosed in the company's 2025 ESG and Sustainability Report published last week, show a 4.54% reduction in energy consumption intensity, a 28.54% drop in water consumption intensity, and total green electricity consumption of 159,279 MWh. All environmental improvements came alongside YOFC's steady global business expansion, with no compromise to production capacity or global supply capacity.

The sustainability progress comes as YOFC continues to expand its global footprint, having held top-ranking market share in optical preforms, optical fiber, and optical cable for 10 consecutive years across more than 100 countries and regions with nine overseas production facilities.

"In the era of artificial intelligence, optical communication infrastructure is becoming a key foundation of the digital economy. Building that infrastructure sustainably is a strategic core of our long-term development, not a separate obligation," said Dan Zhuang, executive director and president of YOFC.

As a frontrunner in smart, low-carbon manufacturing, YOFC runs a network of digitally smart manufacturing facilities. It deploys automation and digital solutions to boost efficiency, product consistency and low-carbon operations. In 2025, YOFC led or contributed to the formulation of 42 industry standards.

On the product side, YOFC's hollow-core optical fiber achieved a minimum attenuation of 0.04 dB/km, a world-leading figure that will allow network operators to build higher-capacity infrastructure at significantly lower energy cost as AI workloads scale.

Sustainability is embedded throughout YOFC's entire business ecosystem. The Company fully adheres to the ISO 28000 supply chain security management system and has formalized security commitments with all raw material and service suppliers. All suppliers have signed the External Party Code of Conduct and integrity agreements, achieving full compliance at a 100% signing rate. Total annual employee training hours amounted to 238,261, underscoring YOFC's ongoing dedication to talent development and social responsibility as integral pillars of its ESG strategy.

With targets of a 50% reduction in greenhouse gas emissions intensity by 2028 compared with 2021 levels and carbon neutrality by 2055, technological innovation and global expansion will remain central to YOFC's green transformation.

"We will continue to advance our green and low-carbon transition, deepen our global presence, and work with industry partners to build a connectivity ecosystem that is more efficient, more intelligent, and more durable," Zhuang said.

China Association of Automobile Manufacturers (CAAM) said that the online rumors claiming that new energy vehicle (NEV) makers were summoned and investigated over power locking issues are false information.

A relevant official of the CAAM stated that recent widely circulated online claims that eight NEV makers were summoned over power locking issues and three carmakers were formally placed under investigation was not stemmed from official source and were entirely inconsistent with the facts.

In response, XPENG-W (09868.HK), BYD COMPANY (01211.HK), GAC Aion, Zeekr, NIO-SW (09866.HK) and AITO shattered the rumors.

Tesla, Inc. (TSLA.US) and LI AUTO-W (02015.HK) told the media that the rumors of being summoned were untrue. Tesla stated that all of its software updates undergo rigorous testing and filing procedures. XPENG-W said that certain social media accounts maliciously hyped the issue through AI applications and included the company on the list, wreaking severe damage to its brand and reputation. After verification, the company has not been summoned recently nor placed under investigation, and it will pursue legal responsibility in accordance with the law.

BYD COMPANY's anti-fraud office issued a statement noting that false online rumors regarding BYD COMPANY being summoned and investigated were deliberately misleading the public and disrupting the online opinion environment. The company has collected evidence and will pursue legal responsibility against relevant parties in accordance with the law.

GAC Aion's legal department also clarified that the company has never been summoned by relevant authorities over the matters mentioned in the false information, nor has it been included on any investigation list. It will pursue legal responsibility against those spreading rumors in accordance with the law.
~

AASTOCKS Financial News
Website: www.aastocks.com

CHENGDU, China, May 8, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that the sNDA (the "Application") for the Company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱^®) was accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China. The application is for sac-TMT in combination with MSD's^[1] anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA^®[2]) as first‑line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have PD-L1 tumor proportion score (TPS) ≥1% and are EGFR-negative and ALK-negative. This acceptance is based on the positive results from the OptiTROP-Lung05 registrational Phase III study, and the application is the fifth indication application for sac-TMT that has been accepted by the NMPA.

The OptiTROP-Lung05 is a randomized, open-label, multicenter, Phase III clinical study that evaluates the efficacy and safety profile of sac-TMT in combination with pembrolizumab versus pembrolizumab monotherapy as first-line treatment for PD-L1-positive locally advanced or metastatic NSCLC. At a pre-specified interim analysis, the study has met its primary endpoint of progression-free survival (PFS) and demonstrated a statistically significant and clinically meaningful improvement as concluded by the Independent Data Monitoring Committee (IDMC). A positive trend in overall survival (OS) was also observed. Notably, the OptiTROP-Lung05 study is the first Phase III study of an immunotherapy and ADC combination to meet its primary endpoint in first-line NSCLC treatment. The study has been selected for an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract number #8506, Lung Cancer –Non-Small Cell Metastatic).

Previously, sac-TMT in combination with intravenous and subcutaneous pembrolizumab for the first-line treatment of patients with locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and ALK-negative was granted Breakthrough Therapy Designation (BTD) by the NMPA. On April 9, 2026, the CDE's official website announced that the Application has entered the priority review and approval process. This marks the fifth sac-TMT indication to enter the CDE's priority review and approval process. Through this process, the review time will be significantly shortened, potentially expediting its approval pathways.

Dr. Michael Ge, CEO of Kelun-Biotech said, "We are delighted to see the acceptance of the fifth indication application for sac-TMT. Compared to immunotherapy alone, the ADC combination with KEYTRUDA^® as first-line treatment for PD-L1-positive NSCLC has achieved not only positive results in PFS, but also a trend toward benefit in OS. This achievement holds significant importance for improving current treatment regimens for lung cancer. We will continue to collaborate with our partners to advance the clinical development and commercialization of sac-TMT, to help more patients with lung cancer and enhance their survival outcomes."

About sac-TMT

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, four indications for sac-TMT have been approved and marketed in China for: 1) unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); 2) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy; 3) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) BC who have received prior ET and at least one line of chemotherapy in advanced setting. The first two indications above have been included in China's National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinically meaningful benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations (BTDs) by the NMPA.

Sac-TMT is the world's first TROP2 ADC drug approved for marketing in lung cancer. A new indication application for sac-TMT in combination with pembrolizumab (KEYTRUDA^®) as first‑line treatment for locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and ALK-negative has been accepted for review by the NMPA, and has entered the priority review and approval process. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD has initiated 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/. 

成都2026年5月8日 /美通社/ -- 四川科倫博泰生物醫藥股份有限公司("科倫博泰"或"公司"，6990.HK)的TROP2 ADC蘆康沙妥珠單抗(sac-TMT, 亦稱SKB264/MK-2870)(佳泰萊^®)的一項sNDA ("該申請")已獲中國國家藥品監督管理局(NMPA)藥品審評中心(CDE)受理，用於聯合默沙東^[1]的抗PD-1單抗帕博利珠單抗(可瑞達^®[2])一線治療PD-L1腫瘤比例分數(TPS)≥1%的EGFR基因突變陰性和ALK陰性的局部晚期或轉移性非小細胞肺癌(NSCLC)成人患者。本次受理是基於OptiTROP-Lung05註冊性III期研究的積極結果，該申請是蘆康沙妥珠單抗(sac-TMT)獲NMPA受理的第五項適應症上市申請。

OptiTROP-Lung05是一項隨機、開放性、多中心III期臨床研究，旨在評估蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗對比帕博利珠單抗單藥一線治療PD-L1陽性的局部晚期或轉移性NSCLC的有效性和安全性。在預設的期中分析中，該研究經獨立資料監查委員會(IDMC)確認已達到無進展生存期(PFS)的主要終點，顯示出統計學意義和臨床意義的顯著改善，並在總生存期(OS)方面觀察到獲益趨勢。值得注意的是，OptiTROP-Lung05研究是首個免疫療法聯合ADC在一線治療NSCLC上達到主要終點的III期臨床研究。該研究已成功入選2026 年美國臨床腫瘤學會(ASCO)年會口頭報告(摘要編號#8506，肺癌-轉移性非小細胞)。

此前，蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗(靜脈輸注和皮下注射)一線治療PD-L1 TPS≥1%的EGFR基因突變陰性和ALK陰性的局部晚期或轉移性NSCLC，已獲NMPA授予突破性療法認定(BTD)。2026年4月9日，CDE官網公佈，該申請已納入優先審評審批程式，這也是蘆康沙妥珠單抗(sac-TMT)納入CDE優先審評審批程式的第五項適應症，通過該程式將大幅縮短審評時限，進一步加快其上市進程。

科倫博泰首席執行官葛均友博士表示："很高興看到蘆康沙妥珠單抗(sac-TMT)第5項適應症上市申請獲得受理。相較免疫單藥治療，ADC聯合K藥一線治療PD-L1陽性NSCLC不僅能在PFS上達到積極結果，在OS方面也顯示出獲益趨勢。這一成果對改善肺癌現有治療方案具有重要意義。科倫博泰將繼續協同合作方推進蘆康沙妥珠單抗(sac-TMT)的臨床開發與商業化，以切實惠及更多肺癌患者，提升患者的生存獲益。" 

關於蘆康沙妥珠單抗(sac-TMT)(佳泰萊^®)

作為公司的核心產品，蘆康沙妥珠單抗(sac-TMT)是一款公司擁有自主智慧財產權的新型TROP2 ADC，針對NSCLC、乳腺癌(BC)、胃癌(GC)、婦科腫瘤及泌尿生殖系統腫瘤等晚期實體瘤。蘆康沙妥珠單抗(sac-TMT)採用獨特雙功能連接子開發而成。該連接子一方面通過與抗TROP2單抗沙妥珠單抗形成不可逆結合，另一方面在溶酶體中可從貝洛替康衍生物拓撲異構酶I抑制劑有效載荷pH敏感裂解，從而最大限度將有效載荷遞送至腫瘤細胞，藥物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2，其後被腫瘤細胞內吞併於細胞內釋放有效載荷KL610023。KL610023作為拓撲異構酶I抑制劑，可誘導腫瘤細胞DNA損傷，進而導致細胞週期阻滯及細胞凋亡。此外，其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性，其可實現旁觀者效應，即殺死鄰近的腫瘤細胞。

於2022年5月，公司授予默沙東(美國新澤西州羅威市默克公司的商號)在大中華區(包括中國內地、香港、澳門及臺灣)以外的所有地區開發、使用、製造及商業化蘆康沙妥珠單抗(sac-TMT)的獨家權利。

截至目前，蘆康沙妥珠單抗(sac-TMT)的4項適應症已於中國獲批上市，分別用於：1)既往至少接受過2種系統治療（其中至少1種治療針對晚期或轉移性階段）的不可切除的局部晚期或轉移性TNBC；2)經EGFR-TKI和含鉑化療治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；3)經EGFR-TKI治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；4)既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療的不可切除或轉移性的HR+/HER2- (IHC 0、IHC 1+或IHC 2+/ISH-) BC；其中前2項適應症已經被納入醫保範圍，將為更多乳腺癌和非小細胞肺癌患者帶來臨床獲益。此外，蘆康沙妥珠單抗(sac-TMT)已獲國家藥品監督管理局(NMPA)授予6項突破性療法認定(BTD)。

蘆康沙妥珠單抗(sac-TMT)是全球首個在肺癌適應症獲批上市的TROP2 ADC藥物。蘆康沙妥珠單抗(sac-TMT)的新增適應症上市申請已獲NMPA受理，用於聯合帕博利珠單抗(可瑞達^®)一線治療PD-L1腫瘤比例分數(TPS)≥1%的EGFR基因突變陰性和ALK陰性的局部晚期或轉移性NSCLC，並被納入優先審評審批程式。目前，科倫博泰已在中國開展9項註冊性臨床研究。默沙東已啟動17項正在進行的蘆康沙妥珠單抗(sac-TMT)作為單藥療法或聯合帕博利珠單抗或其他抗癌藥物用於多種類型癌症的全球性III期臨床研究(這些研究由默沙東申辦並主導)。

關於科倫博泰

四川科倫博泰生物醫藥股份有限公司(簡稱"科倫博泰"，股票代碼：6990.HK)是科倫藥業控股子公司，專注于創新生物技術藥物及小分子藥物的研發、生產、商業化及國際合作。公司圍繞全球和中國未滿足的臨床需求，重點佈局腫瘤、自身免疫和代謝等重大疾病領域，建設國際化藥物研發與產業化平臺，致力於成為在創新藥物領域國際領先的企業。公司目前擁有30余個重點創新藥項目，其中4個項目8個適應症已獲批上市，1個專案處於NDA階段，10餘個專案正處於臨床階段。公司成功構建了享譽國際的專有ADC及新型偶聯藥物平臺OptiDC^™，已有2個ADC項目5個適應症獲批上市，多個ADC或新型偶聯藥物產品處於臨床或臨床前研究階段。更多資訊請訪問官網https://kelun-biotech.com/。

A company linked to Thailand's national AI program is suspected of assisting in the smuggling of Super Micro Computer, Inc. (SMCI.US)'s servers equipped with advanced chips from NVIDIA (NVDA.US) to China, with a total value of tens of billions of US dollars, Bloomberg reported, quoting people with the knowledge of the matter. BABA-W (09988.HK)(BABA.US) was reportedly one of the end customers.

In response, a spokesperson for Alibaba stated that the company has no business dealings with Super Micro Computer, OBON, or any third-party intermediaries allegedly involved in the accusations, and has never participated in any suspected smuggling activities.

The spokesperson added that Alibaba currently does not use, and has never used, any restricted NVIDIA chips in its data centers.
~

AASTOCKS Financial News
Website: www.aastocks.com

–   2026年第一季度總收入為9,960萬美元，反映了一季度預期中的動態因素，包括則樂面臨的某些競爭影響以及衛偉迦與國家醫保目錄續約相關的價格調整

–   Zocilurtatug pelitecan (zoci) 在2026年AACR年會上公布了突出的卓越數據：在伴有腦轉移的小細胞肺癌（SCLC）患者中，顱內經確認客觀緩解率為62.5%；在肺外神經內分泌癌（epNECs）中展現出具有臨床意義的抗腫瘤活性（經確認客觀緩解率為38.2%）。注冊性研究DLLEVATE正在進行中，預計將於2027年上半年完成患者入組

–   與安進和勃林格殷格翰分別達成合作，評估zoci聯合塔拉妥單抗治療小細胞肺癌、zoci聯合obrixtamig治療小細胞肺癌及其他神經內分泌癌（NEC），從而推動zoci成為一款潛在的基石療法

–   ZL-1503 (IL-13/IL-31Rα) 在IMMUNOLOGY2026會議上公布的臨床前數據顯示出快速、持久的雙通路活性，支持更低的給藥頻率，並在包括哮喘在內的特應性疾病中展現了廣泛潛力。1/1b期研究正在進行中，初步數據預計於2026年公布

–   呫諾美林曲司氯銨上市准備工作正在進行中，TIVDAK正處於上市申請審評階段；povetacicept用於IgA腎病的陽性3期研究結果，以及elegrobart用於甲狀腺眼病的陽性3期研究結果，為我們的區域業務提供了更多的增長機會

公司將於今日2026年5月7日美國東部時間上午 8:00（香港時間晚上20:00）舉行電話會議和網絡直播

中國上海和美國馬薩諸塞州劍橋市2026年5月7日 /美通社/ -- 再鼎醫藥有限公司（納斯達克股票代碼：ZLAB；香港聯交所股份代號：9688）今日公布了 2026 年第一季度的財務業績，以及近期的產品亮點和公司進展。

再鼎醫藥創始人、董事長兼首席執行官杜瑩博士表示：「我們正加速推進全球管線的開發，在腫瘤和免疫領域有多項臨床研究正在進行中。第一季度，我們在zoci上取得了顯著進展：在AACR公布的數據進一步證實了zoci在SCLC和epNECs中的差異化優勢；分別與安進和勃林格殷格翰達成合作，共同探索zoci作為潛在基石療法的應用前景；注冊性研究DLLEVATE的患者入組正在快速推進，預計將於2027年上半年完成全部入組。同時，我們也在不斷推進日益壯大的全球臨床研究項目，包括用於特應性皮炎的ZL-1503（IL-13/IL-31Rα）。這些進展充分體現了我們研發引擎的實力，該引擎是為了可以規模化發展並創造差異化的創新產品管線而構建。與此同時，我們業已實現商業化盈利的區域業務為公司提供了穩固的基礎，還有多個近期機會以支持未來的增長。」

再鼎醫藥總裁兼首席運營官Josh Smiley表示：「我們正深化在關鍵市場的布局，以滿足對艾加莫德的潛在需求，同時拓展區域業務覆蓋，為呫諾美林曲司氯銨今年第二季度在中國上市做好准備。中國約有800萬精神分裂症患者，在國家診療指南的支持下，呫諾美林曲司氯銨的上市將使我們能夠向這一重要市場推出幾十年來的首個新型療法，並且希望明年被納入國家醫保藥品目錄。此外，我們預計TIVDAK有望於今年獲得上市批准，povetacicept和elegrobart的3期研究也取得陽性結果，這將為公司帶來更多的增長機遇。我們將繼續聚焦於各項工作中，推動整個商業化產品組合的穩步執行。」

2026年第一季度財務業績

–   2026年第一季度總收入為9,960萬美元，2025年同期為1.065億美元，同比下降6%，2026年第一季度產品收入淨額為9,560萬美元，2025年同期為1.057億美元，同比下降10%，按固定匯率（CER）計算同比下降12%。這一下降主要是由於則樂銷量下降，部分被鼎優樂和紐再樂的銷量增加所抵銷：

• 則樂：2026年第一季度產品收入淨額為3,000萬美元，2025年同期為4,950萬美元。銷量下降是由於奧拉帕利集采後醫院用藥模式發生變化。

• 衛偉迦和衛力迦：2026年第一季度產品收入淨額為1,760萬美元，2025年同期為1,810萬美元。銷量下降主要是由於衛偉迦與國家醫保藥品目錄續約相關的價格調整。

• 鼎優樂：2026年第一季度產品收入淨額為860萬美元，2025年同期為110萬美元。這一增長主要得益於強勁的患者需求和醫院覆蓋范圍的持續擴大，但部分受到供應限制的影響。

• 紐再樂：2026年第一季度產品收入淨額為1,630萬美元，2025年同期為1,510萬美元。這一增長主要是由於市場覆蓋率和滲透率的提升。

–   2026年第一季度的研發開支為6,560萬美元，2025年同期為6,070萬美元。這一增長主要是由於臨床研究相關開支和許可費用的增加。

–   2026年第一季度的銷售、一般及行政開支為6,510萬美元，2025年同期為6,340萬美元。這一增長主要是由於一般銷售開支增加。

–   2026年第一季度經營虧損為6,940萬美元，經調整後扣除折舊、攤銷和以股份為基礎的酬金等非現金支出後為虧損5,190萬美元。本新聞稿末尾附有經營虧損（美國公認會計准則）與調整後經營虧損（非美國公認會計准則）的對比。

–   2026年第一季度虧損淨額為5,100萬美元，歸屬於普通股股東的每股普通股虧損為0.05美元（每份美國存托股份（ADS）虧損為0.46美元），2025年同期虧損淨額為4,840萬美元，每股普通股虧損為0.04美元（每份ADS虧損為0.45美元）。虧損淨額的增加主要是由於產品收入減少及研發開支增加，部分被匯兌收益所抵銷。

–   截至2026年3月31日，現金及現金等價物、短期投資及流動受限制現金總計為7.613億美元，截至2025年12月31日為7.896億美元。

近期公司進展

–   2026年4月，再鼎醫藥任命王軼喆博士為運營合伙人，以加強再鼎醫藥的商業化能力和執行。王軼喆博士在腫瘤和免疫領域的全球商業化運營方面擁有豐富經驗，曾在葛蘭素史克和禮來領導覆蓋中國、美國和英國市場的商業化團隊。

近期管線亮點

自上次財報發布以來的重要產品進展包括：

腫瘤領域管線

• Zocilurtatug Pelitecan (zoci, 靶向DLL3 ADC)（前稱ZL-1310）:

–   2026年4月，再鼎醫藥在美國癌症研究協會（AACR）2026年年會上公布了積極的臨床數據。數據顯示，zoci在既往接受過治療的廣泛期小細胞肺癌（ES-SCLC）伴腦轉移患者中，根據mRANO-BM標准進行的盲態獨立評估，能夠帶來快速且顯著的顱內緩解；此外，zoci在epNEC患者中也展現出了令人鼓舞的數據。

• • 伴腦轉移的SCLC：Zoci顯示經確認的顱內客觀緩解率（iORR）為53.7%，其中在1.6 mg/kg劑量下達到62.5%（10/16），包括完全緩解。值得注意的是，在既往未接受過腦部放療的患者中也觀察到了緩解（9/15，60%），凸顯了這款藥物對顱內病灶的淨效應。Zoci耐受性良好，總人群≥3級的治療相關不良事件 （TRAEs）發生率為19.9%（27/136），而接受1.6mg/kg劑量的患者為16.4%（9/55）。
  • epNECs：觀察到令人鼓舞的抗腫瘤活性，在不同原發部位的epNEC腫瘤中，經確認的客觀緩解率為38.2%。epNEC中的安全性特征與既往在SCLC中觀察到的一致，1b期患者中≥3級TRAEs發生率為15.2%。

–   2026年4月，再鼎醫藥宣布，與安進達成一項全球臨床研究合作，旨在評估zoci聯合安進的IMDELLTRA^®（塔拉妥單抗，一款DLL3/CD3雙特異性T細胞銜接器（TCE））用於治療ES-SCLC；與勃林格殷格翰達成一項臨床研究合作，旨在評估zoci聯合obrixtamig（一款DLL3/CD3雙特異性T細胞銜接器）用於治療SCLC及其他NEC。

免疫、神經科學和感染性疾病領域管線

• ZL-1503 (IL-13/IL-31Rα)：2026年4月，再鼎醫藥公布了ZL-1503臨床前研究的最新數據，數據表明公司內部研發的這款IL-13/IL-31Rα雙特異性抗體可能持續抑制特應性疾病引起的劇烈瘙癢和炎症。這些發現進一步證實了ZL-1503成為治療中重度特應性皮炎及其他IL-13和IL-31驅動的疾病的同類首創療法的潛力。一項全球1/1b期研究正在進行中，再鼎醫藥預計將於2026年下半年公布其全球1期部分的首次人體數據。

• Povetacicept (APRIL/BAFF):
  –   IgA腎病 (IgAN)：2026年3月，再鼎醫藥合作伙伴Vertex公布povetacicept用於IgA腎病的全球3期RAINIER臨床研究中所預先設定的第36周中期分析獲得陽性結果。該研究達到了其主要終點，povetacicept治療組患者的24小時尿蛋白肌酐比值（UPCR）較基線降低了52.0%，與安慰劑相比，UPCR降低了49.8%，具有統計學顯著性和臨床意義（p<0.0001）。Povetacicept總體安全且耐受性良好。再鼎醫藥在大中華區參與了這項全球3期研究。
  –   原發性膜性腎病（pMN）：再鼎醫藥合作伙伴Vertex已完成全球關鍵性2/3期OLYMPUS研究的2期部分患者入組，並已啟動該研究的3期部分。再鼎醫藥在大中華區參與了這項全球研究。

• Elegrobart（胰島素樣生長因子1受體抑制劑, 皮下注射）：再鼎醫藥合作伙伴Viridian Therapeutics公布了elegrobart兩個關鍵性3期臨床研究（分別為用於活動性甲狀腺眼病（TED）的REVEAL-1研究和用於慢性TED的REVEAL-2研究）的陽性主要結果。Elegrobart在兩項研究中總體耐受性良好。再鼎醫藥從Zenas BioPharma處獲得在大中華區開發和商業化elegrobart的獨家授權，並且目前正在大中華區開展一項3期橋接研究。
  –   用於活動性TED的REVEAL-1研究：研究達到了主要終點，治療效果具有高度統計學意義。elegrobart每4周一次給藥方案（Q4W）和每8周一次給藥方案（Q8W）均顯示出快速起效，在第24周時，眼球突出應答率分別達到具有臨床意義的54%和63%，而安慰劑組為18%。此外，Q4W給藥組的活動性TED患者獲得了有意義的復視完全緩解。
  –   用於慢性TED的REVEAL-2研究：研究達到了主要終點，治療效果具有高度統計學意義。elegrobart Q4W和Q8W兩個治療組在第24周時，眼球突出應答率分別達到50%和54%，具有統計學顯著性和臨床意義，而安慰劑組為15%。此外，Q4W組還為慢性TED患者提供了有意義的復視完全緩解。

2026年預期重要裡程碑事件

預期的臨床開發和數據公布

全球管線

Zocilurtatug Pelitecan (zoci, 靶向DLL3 ADC) (前稱ZL-1310)

• 一線廣泛期小細胞肺癌：再鼎醫藥將於2026年下半年公布評估zoci聯合療法（聯合阿替利珠單抗±化療）的1期研究的數據讀出，並計劃基於最新數據在2026年推進zoci至注冊性研究階段。

• 肺外神經內分泌癌：再鼎醫藥將完成zoci用於特定實體瘤的正在進行的全球 1b/2期研究中2期研究的患者入組，並計劃在2026年推進至注冊性開發階段。

ZL-1503 (IL-13/IL-31Rα)

• 再鼎醫藥將於2026年公布全球1/1b期研究的首次人體數據。

區域管線

有望獲得NMPA批准的上市許可申請

• TIVDAK（維替索妥尤單抗，組織因子ADC）用於化療期間或之後病情進展的復發或轉移性宮頸癌
• 腫瘤電場治療(TTFields) 用於局部晚期胰腺癌

預期的數據公布

艾加莫德（FcRn）

• 肌炎：再鼎醫藥合作伙伴argenx將於2026年第三季度公布評估自身免疫性炎性肌病（AIM，肌炎）全球2/3期ALKIVIA研究的主要結果。再鼎醫藥在大中華區參與了這項研究。

Elegrobart (胰島素樣生長因子1受體抑制劑, 皮下注射)

• 再鼎醫藥將在2026年第三季度在中國完成3期注冊性研究的患者入組。

電話會議和網絡直播相關信息

再鼎醫藥將於今天（2026年5月7日）美國東部時間上午8點（香港時間晚上8點）舉行電話會議和網絡直播。與會者可以訪問公司網站http://ir.zailaboratory.com參與實時網絡直播。如要參加電話會議，需提前注冊。

詳細信息如下：

• 網絡直播（推薦）注冊鏈接：https://edge.media-server.com/mmc/p/s7q4ox5h
• 電話撥入注冊鏈接：https://register-conf.media-server.com/register/BI802954894429400baf012f775762af29

所有與會者都必須在電話會議之前通過上方鏈接完成在線注冊。注冊成功後，您將收到確認郵件，內含撥入電話會議的具體信息。

會議結束後，您可通過訪問再鼎醫藥網站觀看回放。

關於再鼎醫藥

再鼎醫藥（納斯達克股票代碼：ZLAB； 香港聯交所股份代號：9688）是一家以研發為基礎、處於商業化階段的創新型生物制藥公司，總部位於中國和美國。我們致力於通過創新產品的發現、開發和商業化解決腫瘤、免疫、神經科學和感染性疾病領域未被滿足的巨大醫療需求。我們的目標是利用我們的能力和資源為人類健康帶來積極影響。

有關再鼎醫藥的更多信息，請訪問www.zailaboratory.com或關注https://x.com/ZaiLab_Global。

非美國公認會計准則指標

除了根據美國公認會計准則呈現的業績外，我們還披露了經調整的增長率，以排除由於外幣折算為美元產生差異的影響。我們還提供了調整後的經營虧損指標，該指標對美國公認會計准則經營虧損進行了調整，以排除某些非現金支出（包括折舊攤銷以及以股份為基礎的酬金）的影響。我們稱之為「實現非美國公認會計准則經營利潤盈利」。這些調整後的增長率和調整後的經營虧損是非美國公認會計准則指標。我們認為這些非美國公認會計准則指標對於了解我們的經營業績和財務業績非常重要，並為投資者提供了趨勢的更多視角。盡管我們認為非美國公認會計准則財務指標可以增強投資者對我們業務和業績的了解，但這些非美國公認會計准則財務指標不應被視為相應的美國公認會計准則財務指標的唯一替代指標。

再鼎醫藥前瞻性聲明

本新聞稿包含了與以下方面相關的前瞻性陳述，包括：我們的策略和計劃；我們的業務、商業化產品和管線項目的潛力和預期；我們的目標、目的和重點事項以及我們基於增長戰略的預期（包括我們對商業化產品和上市、臨床階段產品、收入增長、盈利能力和現金流的預期）；臨床開發計劃和相關臨床研究；臨床研究數據、數據解讀和發布；與藥物開發和商業化相關的風險和不確定性；注冊相關的討論、提交、申請、獲批和時間線；我們及我們合作伙伴的產品和候選產品的潛在裨益、安全性和有效性；投資、合作和業務拓展活動的預期收益和潛力；我們的盈利能力和實現盈利的時間線；我們未來的財務和經營業績；以及財務指導（包括我們的資本配置和投資策略以及我們預期實現盈利的途徑）。除對過往事實的陳述外，本新聞稿中包含的所有陳述均屬前瞻性陳述，並可通過諸如「旨在」、「預計」、「認為」、「有可能」、「估計」、「預期」、「預測」、「目標」、「打算」、「可能」、「計劃」、「准備」、「定位」、「可能的」、「潛在」、「將會」、「將要」等詞匯和其他類似表述予以識別。該等陳述構成《1995年美國私人證券訴訟改革法案》中定義的「前瞻性陳述」。前瞻性陳述並非對未來表現的擔保或保證。前瞻性陳述基於我們截至本新聞稿發布之日的預期和假設，並且受到固有不確定性、風險以及可能與前瞻性陳述所預期的情況存在重大差異的情勢變更的影響。對於我們在前瞻性陳述中披露的計劃、意圖、預期或預測，我們可能無法實際實現、執行或滿足，請勿過分依賴此等前瞻性陳述。實際結果可能受各種重要因素的影響而與前瞻性陳述所示存在重大差異，該等因素包括但不限於：(1)我們成功商業化自身已獲批上市產品並從中產生收入的能力；(2)我們為自身的運營和業務活動獲取資金的能力；(3)我們候選產品的臨床開發和臨床前開發的結果；(4)相關監管機構對我們的候選產品作出審批決定的內容和時間；(5)與在中國營商有關的風險；和(6)我們向美國證券交易委員會（SEC）提交的最新年報和季報以及其他報告中指出的其他因素。我們預計後續事件和發展將導致我們的預期和假設改變，但除法律要求之外，不論是出於新信息、未來事件或其他原因，我們均無義務更新或修訂任何前瞻性陳述。該等前瞻性陳述不應被視為我們在本新聞稿發布之日後任何日期的意見而加以信賴。

如需查閱公司向SEC提交的文件，請訪問公司網站www.zailaboratory.com 和SEC網站www.SEC.gov。

LOS ANGELES, May 7, 2026 /PRNewswire/ -- TCL CSOT, a global leader in advanced display technologies and a subsidiary of TCL Technology, is presenting a holistic vision for the future of mobility at SID Display Week 2026. For automotive applications, TCL CSOT demonstrates how different in‑car positions and functions can be served by diverse display technologies — from Inkjet-printed OLED (IJP OLED) to Micro LED to LCD — each tailored to specific needs. At the center of this vision is the Intelligent Cockpit Display Suite 3.0, a flagship solution that integrates these technologies into a unified ecosystem, redefining how drivers and passengers interact with the vehicle.

Intelligent Cockpit Display Suite 3.0: A New Benchmark for In-Car Displays

At the heart of the suite are two world‑first innovations: the World's First IJP OLED Sliding Central Control Display (28") and the World's First IJP OLED Curved Armrest Display (28"). Both are built on the same IJP OLED technology, which is inherently flexible and can be adapted into countless other shapes and applications beyond the two showcased today. This versatility, combined with TCL CSOT's decade‑long leadership in IJP OLED and the construction of its world's first 8.6‑generation IJP OLED production line (t8), sets a new standard for cockpit innovation. These innovations redefine the in‑car experience with superior image quality, power efficiency, and design flexibility at reduced cost.

• The World's First IJP OLED Sliding Central Control Display (28") features an innovative curling design that allows free extension and retraction, injecting a futuristic feel into the cabin. When parked, it can be fully stored to release space; during driving, it unfolds with a single touch to serve both driver and passenger applications. Flexible display modes — ½, ⅔, or full screen — support multi‑scenario use, while split‑screen functionality enables navigation, entertainment, and vehicle control to run in parallel. Deeply integrated with the intelligent ecosystem, it transforms static aesthetics into dynamic interaction, making every trip a dual experience of technology and comfort.

• The World's First IJP OLED Curved Armrest Display (28") complements this innovation by combining IJP OLED's vivid clarity with ergonomic design. Its curved form enhances fingertip sliding and visual extension, breaking the limitations of traditional flat screens. From intuitive interconnection to seamless scene‑based applications, it empowers travel with technology, redefining comfort and efficiency while adding a sense of occasion to every interaction.

Together, the sliding and curved IJP OLED displays balance practicality with futuristic elegance, elevating the cockpit into a truly immersive environment.

Complementing the OLED centerpiece are advanced HUD solutions that expand the ecosystem of intelligent displays. The World's First Ultra High Brightness Micro LED AR‑HUD Display (4.6") projects crystal‑clear images directly onto the windshield, achieving 18,000 nits of luminance at the eye and a wide field of view that remains sharp even under direct sunlight. It provides intuitive navigation, safe driving cues, and immersive interaction. Meanwhile, the World-Leading High Brightness & Low-Power-Consumption P-HUD Display (12") reimagines the dashboard by projecting essential information — speed, navigation, and warnings — into a dedicated area within the driver's line of sight. This enables "zero eye movement" interaction, ensuring critical data is always accessible without distraction, while maintaining high brightness at remarkably low power.

Together, these innovations highlight TCL CSOT's vision of the cockpit as more than just a collection of displays — it is the intelligent hub of future mobility. By uniting IJP OLED, Micro LED, and LCD technologies, the suite creates a seamless environment where information, interaction, and design converge. The result is a driving experience that feels intuitive and immersive, with displays that adapt fluidly to both functional needs and aesthetic expectations.

About TCL CSOT
Established in 2009, TCL China Star Optoelectronics Technology Co., Ltd. (TCL CSOT) is a leading global innovator in display technologies. Its LCD, OLED, and MLED solutions power applications across TVs, smartphones, tablets, laptops, monitors, automotive systems, VR/XR, and commercial displays. With a clear strategic direction set by its advanced display technology brand APEX, TCL CSOT invests continuously and strategically in R&D, driven by a mission to amaze, protect and inspire all people through endlessly innovative display technology. As part of TCL's Worldwide Olympic Partnership, TCL CSOT is proud to deliver display solutions that elevate experiences on the global stage.

LOS ANGELES, May 7, 2026 /PRNewswire/ -- TCL CSOT, a global leader in advanced display technologies and a subsidiary of TCL Technology, is demonstrating how XR innovation can expand imagination and redefine interaction at SID Display Week 2026. This focus reflects the company's APEX philosophy, with its pillar of X‑Unlimited Imaginative Potential — exploring future‑oriented display forms designed to enrich human experience.

"XR devices are driving the next revolution in human-machine interaction," said Zhifu Li, VP of TCL CSOT, GM of XR BU of TCL CSOT. "Within an ultra-compact 0.28-inch form factor, TCL CSOT has achieved a retina-level pixel density of 5131PPI. Powered by full-color silicon-based Micro LED technology, we have set a new benchmark for next-generation lightweight, high-performance displays, creating a true 'smart window' into immersive digital experiences for AR and AI glasses."

Retina‑Level Clarity for AR and VR

TCL CSOT's World's Highest PPI Single-Chip Full-Color Si-Micro LED Display (0.28") sets a new milestone in ultra‑compact display technology. Built on a silicon substrate with monolithic full‑color Micro LED integration, this 0.28‑inch panel achieves a resolution of 1280×720 and an unprecedented pixel density of 5131PPI, delivering razor‑sharp visuals with no visible pixilation.

Leveraging the self‑emissive advantages of Micro LED, the display offers high brightness, deep contrast, and a wide color gamut, creating a "retina‑level" experience for near‑eye applications such as AR glasses and ultra‑thin VR devices. With its miniaturized form factor, ultra‑high resolution, and low power consumption, this innovation establishes a new benchmark for lightweight, high‑performance display solutions and marks a significant leap forward in micro‑display applications.

Immersive Fidelity for Next Gen XR

To advance ultra‑high‑definition XR experiences, TCL CSOT has introduced the World's Highest 1700PPI Real RGB G-OLED Display (2.24"). Built on glass‑based OLED architecture, it achieves 1700PPI density and 2600×2784 real RGB resolution, delivering images of exceptional sharpness and fidelity.

With a 1M:1 contrast ratio and 120Hz refresh rate, the display ensures fluid motion and vivid detail, enhanced by OLED's inherent advantages — microsecond response time, deep contrast, and low power consumption. This innovation not only elevates XR experiences but also extends its impact through ultra‑high‑density circuit technology adaptable to premium consumer electronics and industrial applications, unlocking vast market potential for XR.

Expanding the XR Portfolio

These pioneering XR displays are part of a broader portfolio TCL CSOT is showcasing at SID Display Week 2026. Underscoring its leadership across immersive display technologies, TCL CSOT is also presenting a diverse range of other XR innovations. These include the World's Highest-Res Single-Chip Multi-Color Si-Micro LED Display (0.28"), the World's Highest 2200PPI LCD XR Display (2.48") and World's Highest MP 1512PPI XR Display Paired With Cockpit (3.59"). Together, these breakthroughs highlight TCL CSOT's ability to redefine performance standards and shape the future of XR experiences.

Anchored in its human-centric APEX philosophy, TCL CSOT is ensuring that XR innovation is not only technologically advanced but also meaningful, accessible, and designed to enrich human imagination across all future applications.

About TCL CSOT

Established in 2009, TCL China Star Optoelectronics Technology Co., Ltd. (TCL CSOT) is a leading global innovator in display technologies. Its LCD, OLED, and MLED solutions power applications across TVs, smartphones, tablets, laptops, monitors, automotive systems, VR/XR, and commercial displays. With a clear strategic direction set by its advanced display technology brand APEX, TCL CSOT invests continuously and strategically in R&D, driven by a mission to amaze, protect and inspire all people through endlessly innovative display technology. As part of TCL's Worldwide Olympic Partnership, TCL CSOT is proud to deliver display solutions that elevate experiences on the global stage.